Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Eloxx Pharmaceuticals, Inc. Common Stock

ELOX

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $12.24 – $13.26
Volume 14,122
Market cap $52M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$52.11M
Price / earnings
—
Price / book
-2.31×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.32×

Profitability

Earnings per share
-$3.47
Return on assets
-827.28%
Return on equity
62.67%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.17×
Current ratio
0.07×
Quick ratio
0.07×
Cash ratio
0.05×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
—

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ELOX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2023 Dec 31, 2023Q3 FY2023 Sep 30, 2023Q2 FY2023 Jun 30, 2023Q1 FY2023 Mar 31, 2023
Revenue$0$0$0$0—$0——
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0—$0——
Selling, general and administrative$1.61M$2.14M$684K$712K—$2.39M$1.8M$2M
Research and development$2.84M$1.66M$898K$510K—$1.25M$2.34M$3.49M
Total operating expenses$4.45M$3.8M$1.58M$1.22M—$3.64M$4.14M$5.48M
Operating income-$4.45M-$3.8M-$1.58M-$1.22M—-$3.64M-$4.14M-$5.48M
Interest expense$0$0$0$0—$0——
Income before taxes-$4.5M-$3.75M-$1.89M-$1.71M—-$3.59M-$4.34M-$6.23M
Income taxes$0$0$0$0—$0——
Net income-$4.5M-$3.75M-$1.89M-$1.71M—-$3.59M-$4.34M-$6.23M
Net income attributable to common shareholders-$4.5M-$3.75M-$1.89M-$1.71M—-$3.59M-$4.34M-$6.23M
EBITDA-$4.45M-$3.8M-$1.58M-$1.22M$0-$3.45M-$3.96M-$5.3M
Basic earnings per share-$0.66-$0.08-$5.45-$0.45—-$1.31-$1.96-$2.88
Diluted earnings per share-$0.66-$0.08-$5.45-$0.45—-$1.31-$1.96-$2.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

The article discusses the prevalence and impact of rare genetic disorders, which affect over 350 million people worldwide. It highlights the challenges in treating these conditions, including limited treatment options and underfunding for research. The article also provides an overview of the market analysis for various rare genetic disorders, including Usher Syndrome, Alport Syndrome, Menkes Disease, and others.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 1, 20261-for-11reverse split
Dec 2, 20221-for-40reverse split